Supplementary Data

Supplementary data 1: Cell line information. * Originated from same individual; ** Derived from FEMX1. Data source: 1 (Cellosaurus 29), 2 (this study and 31), 330, 4 (this study and 32). Zygosity abbreviations: het, heterozygous; hom, homozygous; hemi, hemizygous. Other abbreviations: Mut, mutant; Ter, termination codon. Supplementary data 2: Drug information. Supplementary data 3: Source data for Figure 4B Supplementary data 4: Source data for Figure 5D Supplementary data 5: Source data for Figure 5E Supplementary data 6: Source data for Figure 6B Supplementary data 7: Source data for Suppl. Figure S6B Supplementary data 8: Source data for Suppl. Figure S13 Supplementary data 9: Drug Activity Range between the ED10 and ED90. Mean and median for each drug across all samples. Supplementary data 10: Estimated effective drug concentration based on the ED10, ED20, ED50 and ED90 for each drug and sample. Supplementary data 11: Area under the curve (AUC) for each drug and sample. Supplementary data 12: Drug sensitivity data with the viability and inhibition based on the normalized CPS measurements, including raw CPS measurements. Supplementary data 13: Z’-factor scores for each plate. Mean and median for each sample, as well as across all samples. Supplementary data 14: Drug interaction scores for synergy and antagonism based on the median rVUS, ranked by synergy score for all drug combinations and samples. Supplementary data 15: Dose−Response matrices for all samples and drug combinations. upplementary data 16: Drug interaction plots from bayesynergy with the estimated drug sensitivity scores (DSS and rVUS), dose response curves and interaction surfaces.